A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Dr Rashida Karmali, a Uganda-born cancer scientist based in New York, has developed a groundbreaking drug, ...
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...
GlobalData on MSN2d
Pfizer’s colon cancer combo approval further supported by Phase III winPfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...
Positive Phase 1b Data Confirms Overdose Protection for Highest ... In 2024, PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), and had its ...
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback